Corinne Johnson
Stock Analyst at Goldman Sachs
(3.19)
# 1,083
Out of 5,146 analysts
17
Total ratings
50%
Success rate
19.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Neutral | $37 → $39 | $29.66 | +31.49% | 1 | Jan 15, 2026 | |
| IMVT Immunovant | Maintains: Neutral | $18 → $28 | $27.23 | +2.83% | 2 | Dec 15, 2025 | |
| MBX MBX Biosciences | Initiates: Sell | $18 | $35.64 | -49.49% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $14.37 | +39.18% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $20.75 | +15.66% | 2 | Sep 5, 2025 | |
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $72.80 | -24.45% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $23.29 | +41.69% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $131.15 | +38.77% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $56.99 | -12.27% | 3 | May 14, 2024 |
TG Therapeutics
Jan 15, 2026
Maintains: Neutral
Price Target: $37 → $39
Current: $29.66
Upside: +31.49%
Immunovant
Dec 15, 2025
Maintains: Neutral
Price Target: $18 → $28
Current: $27.23
Upside: +2.83%
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $35.64
Upside: -49.49%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $14.37
Upside: +39.18%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $20.75
Upside: +15.66%
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $72.80
Upside: -24.45%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $23.29
Upside: +41.69%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $131.15
Upside: +38.77%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $56.99
Upside: -12.27%